Agents for preventing and treating disorders involving modulation of the ryanodine receptors
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61P-009/00
A61K-031/553
A61K-031/554
C07D-281/02
출원번호
US-0938098
(2010-11-02)
등록번호
US-8710045
(2014-04-29)
발명자
/ 주소
Marks, Andrew Robert
Landry, Donald W.
Deng, Shixian
출원인 / 주소
The Trustees of Columbia University in the City of New York
대리인 / 주소
Winston & Strawn LLP
인용정보
피인용 횟수 :
0인용 특허 :
133
초록▼
The present invention provides compounds of Formula I and salts, hydrates, solvates, complexes, and prodrugs thereof. The present invention further provides methods for synthesizing compounds of Formula I. The invention additionally provides pharmaceutical compositions comprising the compounds of F
The present invention provides compounds of Formula I and salts, hydrates, solvates, complexes, and prodrugs thereof. The present invention further provides methods for synthesizing compounds of Formula I. The invention additionally provides pharmaceutical compositions comprising the compounds of Formula I and methods of using the pharmaceutical compositions of Formula I to treat and prevent disorders and diseases associated with the RyR receptors that regulate calcium channel functioning in cells.
대표청구항▼
1. A compound which is selected from the group consisting of formula I-g, I-h, I-k-1, I-l-1, or I-m-1: wherein (a) the compound of formula I-g or I-h is: wherein W is S or O;n is 0, 1, or 2;q is 0, 1, 2, 3, or 4;each R is located at position 6, 7, 8 or 9 on the benzothiazepine ring;each R is indepen
1. A compound which is selected from the group consisting of formula I-g, I-h, I-k-1, I-l-1, or I-m-1: wherein (a) the compound of formula I-g or I-h is: wherein W is S or O;n is 0, 1, or 2;q is 0, 1, 2, 3, or 4;each R is located at position 6, 7, 8 or 9 on the benzothiazepine ring;each R is independently selected from the group consisting of halogen, —OH, —NH2, —NO2, —CN, —CF3, —OCF3, —N3, —SO3H, —S(═O)2alkyl, —S(═O)alkyl, —OS(═O)2CF3, acyl, alkyl, alkoxyl, alkylamino, alkylthio, cycloalkyl, aryl, heterocyclyl, heterocyclylalkyl, alkenyl, alkynyl, (hetero-)aryl, (hetero-)arylthio, and (hetero-)arylamino; wherein each acyl, alkyl, alkoxyl, alkylamino, alkylthio, cycloalkyl, aryl, heterocyclyl, heterocyclylalkyl, alkenyl, alkynyl, (hetero-)aryl, (hetero-)arylthio, and (hetero-)arylamino may be substituted or unsubstituted;R15 and R16 independently are selected from the group consisting of H, acyl, alkenyl, alkoxyl, OH, NH2, alkyl, alkylamino, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl; wherein each acyl, alkenyl, alkoxyl, alkyl, alkylamino, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl may be substituted or unsubstituted; and optionally R15 and R16 together with the N to which they are bonded may form a heterocycle which may be substituted or unsubstituted; andR′ and R″ are independently selected from the group consisting of H, halogen, —OH, —NH2, —NO2, —CN, —CF3, —OCF3, —N3, —SO3H, —S(═O)2alkyl, —S(═O)alkyl, —OS(═O)2CF3, acyl, alkyl, alkoxyl, alkylamino, alkylthio, cycloalkyl, aryl, heteroaryl, heterocyclyl, heterocyclylalkyl, alkenyl, alkynyl, (hetero-)arylthio, and (hetero-)arylamino; wherein each acyl, alkyl, alkoxyl, alkylamino, cycloalkyl, aryl, heteroaryl, heterocyclyl, heterocyclylalkyl, alkenyl, alkynyl, and (hetero-)arylthio may be substituted or unsubstituted; provided that when q is 0 and n is 0, then —C(═W)NR15R16 is not —C(═O)NH2, —C(═O)NHPh, —C(═S)NH-nButyl, or —C(═O)NHC(═O)CH2Cl;when q is 0, n is 0 or 2, then —C(═W)NR15R16 is not —C═ONHPh, —C═ONHCOCH2Cl, —C═ONH2, —C═ONH(n-Bu), —C═S(NHPh), —C═S(NHCOCH2Cl), —C═S(NH2), or —C═SNH(n-Bu);(b) the compound of formula I-k-1 is: whereinn is 0, 1, or 2;R18 is selected from the group consisting of —NR15R16, —C(═O)—NR15R16, —OR15, —C(═O)—OR15, alkyl, aryl, cycloalkyl and heterocyclyl, wherein each alkyl, aryl, cycloalkyl and heterocyclyl may be unsubstituted or substituted;R15 and R16 independently are selected from the group consisting of H, acyl, alkenyl, alkoxyl, OH, NH2, alkyl, alkylamino, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl; wherein each acyl, alkenyl, alkoxyl, alkyl, alkylamino, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl may be substituted or unsubstituted; and optionally R15 and R16 together with the N to which they are bonded may form a heterocycle which may be substituted or unsubstituted;p is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;R′ is selected from the group consisting of halogen, —OH, —NH2, —NO2, —CN, —CF3, —OCF3, —N3, —SO3H, —S(═O)2alkyl, —S(═O)alkyl, —OS(═O)2CF3, acyl, alkyl, alkoxyl, alkylamino, alkylthio, cycloalkyl, aryl, heteroaryl, heterocyclyl, heterocyclylalkyl, alkenyl, alkynyl, (hetero-)arylthio, and (hetero-)arylamino; wherein each acyl, alkyl, alkoxyl, alkylamino, cycloalkyl, aryl, heteroaryl, heterocyclyl, heterocyclylalkyl, alkenyl, alkynyl, and (hetero-)arylthio may be substituted or unsubstituted; andR″ is H;provided that when n is 0, and R′ is OH or C1-C3 alkoxyl, then —(CH2)p—R18 is not —(CH2)3-4-benzylpiperidine;(c) the compound of formula I-l-1 is: whereinn is 0, 1, or 2;R6 is selected from the group consisting of —OR15, —NHNR15R16, —NHOH, —CH2X, acyl, alkenyl, alkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl; wherein each acyl, alkenyl, alkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl may be substituted or unsubstituted;R15 and R16 independently are selected from the group consisting of H, acyl, alkenyl, alkoxyl, OH, NH2, alkyl, alkylamino, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl; wherein each acyl, alkenyl, alkoxyl, alkyl, alkylamino, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl may be substituted or unsubstituted; and optionally R15 and R16 together with the N to which they are bonded may form a heterocycle which may be substituted or unsubstituted;X is selected from the group consisting of halogen, —CN, —CO2R15, —C(═O)NR15R16, —NR15R16, —OR15, —SO2R7, and —P(═O)R8R9;R7 is selected from the group consisting of —OR15, —NR15R16, —NHNR15R16, —NHOH, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl; wherein each alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl may be substituted or unsubstituted;R8 and R9 independently are selected from the group consisting of OH, acyl, alkenyl, alkoxyl, alkyl, alkylamino, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl; wherein each acyl, alkenyl, alkoxyl, alkyl, alkylamino, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl may be substituted or unsubstituted; andR′ and R″ are independently selected from the group consisting of H, halogen, —OH, —NH2, —NO2, —CN, —CF3, —OCF3, —N3, —SO3H, —S(═O)2alkyl, —S(═O)alkyl, —OS(═O)2CF3, acyl, alkyl, alkoxyl, alkylamino, alkylthio, cycloalkyl, aryl, heteroaryl, heterocyclyl, heterocyclylalkyl, alkenyl, alkynyl, (hetero-)arylthio, and (hetero-)arylamino; wherein each acyl, alkyl, alkoxyl, alkylamino, cycloalkyl, aryl, heteroaryl, heterocyclyl, heterocyclylalkyl, alkenyl, alkynyl, and (hetero-) arylthio may be substituted or unsubstituted; or(d) the compound of formula I-m-1 is: whereinn is 0, 1, or 2;R8 and R9 independently are selected from the group consisting of OH, acyl, alkenyl, alkoxyl, alkyl, alkylamino, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl; wherein each acyl, alkenyl, alkoxyl, alkyl, alkylamino, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl may be substituted or unsubstituted;R′ and R″ are independently selected from the group consisting of H, halogen, —OH, —NH2, —NO2, —CN, —CF3, —OCF3, —N3, —SO3H, —S(═O)2alkyl, —S(═O)alkyl, —OS(═O)2CF3, acyl, alkyl, alkoxyl, alkylamino, alkylthio, cycloalkyl, aryl, heteroaryl, heterocyclyl, heterocyclylalkyl, alkenyl, alkynyl, (hetero-)arylthio, and (hetero-) arylamino; wherein each acyl, alkyl, alkoxyl, alkylamino, cycloalkyl, aryl, heteroaryl, heterocyclyl, heterocyclylalkyl, alkenyl, alkynyl, and (hetero-) arylthio may be substituted or unsubstituted. 2. The compound of claim 1 having the formula of I-g or I-h: wherein W is S or O;n is 0, 1, or 2;q is 0, 1, 2, 3, or 4;each R is located at position 6, 7, 8 or 9 on the benzothiazepine ring;each R is independently selected from the group consisting of halogen, —OH, —NH2—NO2, —CN, —CF3—OCF3, —N3—SO3H, —S(═O)2alkyl, —S(═O)alkyl, —OS(═O)2CF3, acyl, alkyl, alkoxyl, alkylamino, alkylthio, cycloalkyl, aryl, heterocyclyl, heterocyclylalkyl, alkenyl, alkynyl, (hetero-) aryl, (hetero-)arylthio, and (hetero-)arylamino; wherein each acyl, alkyl, alkoxyl, alkylamino, alkylthio, cycloalkyl, aryl, heterocyclyl, heterocyclylalkyl, alkenyl, alkynyl, (hetero-)aryl, (hetero-)arylthio, and (hetero-)arylamino may be substituted or unsubstituted;R15 and R16 independently are selected from the group consisting of H, acyl, alkenyl, alkoxyl, OH, NH2, alkyl, alkylamino, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl; wherein each acyl, alkenyl, alkoxyl, alkyl, alkylamino, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl may be substituted or unsubstituted; and optionally R15 and R16 together with the N to which they are bonded may form a heterocycle which may be substituted or unsubstituted; andR′ and R″ are independently selected from the group consisting of H, halogen, —OH, —NH2, —NO2, —CN, —CF3, —OCF3, —N3, —SO3H, —S(═O)2alkyl, —S(═O)alkyl, —OS(═O)2CF3, acyl, alkyl, alkoxyl, alkylamino, alkylthio, cycloalkyl, aryl, heteroaryl, heterocyclyl, heterocyclylalkyl, alkenyl, alkynyl, (hetero-)arylthio, and (hetero-) arylamino; wherein each acyl, alkyl, alkoxyl, alkylamino, cycloalkyl, aryl, heteroaryl, heterocyclyl, heterocyclylalkyl, alkenyl, alkynyl, and (hetero-) arylthio may be substituted or unsubstituted. 3. The compound of claim 2, wherein W is O. 4. The compound of claim 3, wherein R15 and R16 independently are selected from the group consisting of H, OH, NH2, alkyl, alkylamino, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl; wherein each alkyl, alkylamino, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl may be substituted; and optionally R15 and R16 together with the N to which they are bonded may form a heterocycle which may be substituted. 5. The compound of claim 1, having the formula I-k-1: whereinn is 0, 1, or 2;R18 is selected from the group consisting of —NR15R16, —C(═O)—NR15R16, —OR15, —C(═O)—OR15, alkyl, aryl, cycloalkyl and heterocyclyl, wherein each alkyl, aryl, cycloalkyl and heterocyclyl may be unsubstituted or substituted;R15 and R16 independently are selected from the group consisting of H, acyl, alkenyl, alkoxyl, OH, NH2, alkyl, alkylamino, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl; wherein each acyl, alkenyl, alkoxyl, alkyl, alkylamino, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl may be substituted or unsubstituted; and optionally R15 and R16 together with the N to which they are bonded may form a heterocycle which may be substituted or unsubstituted;p is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;R′ is selected from the group consisting of halogen, —OH, —NH2, —NO2, —CN, —CF3, —OCF3, —N3, —SO3H, —S(═O)2alkyl, —S(═O)alkyl, —OS(═O)2CF3, acyl, alkyl, alkoxyl, alkylamino, alkylthio, cycloalkyl, aryl, heteroaryl, heterocyclyl, heterocyclylalkyl, alkenyl, alkynyl, (hetero-)arylthio, and (hetero-)arylamino; wherein each acyl, alkyl, alkoxyl, alkylamino, cycloalkyl, aryl, heteroaryl, heterocyclyl, heterocyclylalkyl, alkenyl, alkynyl, and (hetero-)arylthio may be substituted or unsubstituted; andR″ is H. 6. The compound of claim 1 having the formula I-l-1: whereinn is 0, 1, or 2;R6 is selected from the group consisting of —OR15, —NHNR15R16, —NHOH, —CH2X, acyl, alkenyl, alkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl; wherein each acyl, alkenyl, alkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl may be substituted or unsubstituted;R15 and R16 independently are selected from the group consisting of H, acyl, alkenyl, alkoxyl, OH, NH2, alkyl, alkylamino, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl; wherein each acyl, alkenyl, alkoxyl, alkyl, alkylamino, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl may be substituted or unsubstituted; and optionally R15 and R16 together with the N to which they are bonded may form a heterocycle which may be substituted or unsubstituted;X is selected from the group consisting of halogen, —CN, —CO2R15, —C(═O)NR15R16, —NR15R16, —OR15, —SO2R7, and —P(═O)R8R9;R7 is selected from the group consisting of —OR15, —NR15R16, —NHNR15R16, —NHOH, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl; wherein each alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl may be substituted or unsubstituted;R8 and R9 independently are selected from the group consisting of OH, acyl, alkenyl, alkoxyl, alkyl, alkylamino, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl; wherein each acyl, alkenyl, alkoxyl, alkyl, alkylamino, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl may be substituted or unsubstituted; andR′ and R″ are independently selected from the group consisting of H, halogen, —OH, —NH2, —NO2, —CN, —CF3, —OCF3, —N3, —SO3H, —S(═O)2alkyl, —S(═O)alkyl, —OS(═O)2CF3, acyl, alkyl, alkoxyl, alkylamino, alkylthio, cycloalkyl, aryl, heteroaryl, heterocyclyl, heterocyclylalkyl, alkenyl, alkynyl, (hetero-)arylthio, and (hetero-)arylamino; wherein each acyl, alkyl, alkoxyl, alkylamino, cycloalkyl, aryl, heteroaryl, heterocyclyl, heterocyclylalkyl, alkenyl, alkynyl, and (hetero-) arylthio may be substituted or unsubstituted. 7. The compound of claim 1 having the formula I-m-1: whereinn is 0, 1, or 2;R8 and R9 independently are selected from the group consisting of OH, acyl, alkenyl, alkoxyl, alkyl, alkylamino, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl; wherein each acyl, alkenyl, alkoxyl, alkyl, alkylamino, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl may be substituted or unsubstituted;R′ and R″ are independently selected from the group consisting of H, halogen, —OH, —NH2, —NO2, —CN, —CF3, —OCF3, —N3, —SO3H, —S(═O)2alkyl, —S(═O)alkyl, —OS(═O)2CF3, acyl, alkyl, alkoxyl, alkylamino, alkylthio, cycloalkyl, aryl, heteroaryl, heterocyclyl, heterocyclylalkyl, alkenyl, alkynyl, (hetero-)arylthio, and (hetero-) arylamino; wherein each acyl, alkyl, alkoxyl, alkylamino, cycloalkyl, aryl, heteroaryl, heterocyclyl, heterocyclylalkyl, alkenyl, alkynyl, and (hetero-) arylthio may be substituted or unsubstituted. 8. A compound selected from the group consisting of: and a salt thereof. 9. The compound of claim 1, wherein the compound is S64 or its HCl salt. 10. The compound of claim 8, wherein the compound is S107 or its pharmaceutically acceptable salt. 11. The compound of claim 10, wherein the salt is the HCl salt. 12. The compound of claim 1, wherein the compound is S111 or its pharmaceutically acceptable salt. 13. The compound of claim 12, wherein the salt is the HCl salt. 14. A pharmaceutical composition comprising a compound according to claim 1, and a pharmaceutically acceptable carrier. 15. A pharmaceutical composition comprising one of the compounds according to claim 8, and a pharmaceutically acceptable carrier. 16. A method of treating a disorder or a disease in a subject, or reducing the risk of sudden cardiac death in a subject who is considered to be subject to such risk, comprising administering to the subject a therapeutically effective amount of a compound according to claim 1 to effectuate the treatment, wherein the disorder or disease is selected from the group consisting of cardiac disorders and diseases, skeletal muscular disorders and diseases, cognitive disorders and diseases, malignant hyperthermia, diabetes, and sudden infant death syndrome; wherein the cardiac disorders and diseases are selected from the group consisting of irregular heartbeat disorders and diseases; exercise-induced irregular heartbeat disorders and diseases; heart failure, congestive heart failure; chronic obstructive pulmonary disease; and high blood pressure; wherein the skeletal muscular disorders and diseases are selected from the group consisting of skeletal muscle fatigue, exercise-induced skeletal muscle fatigue, muscular dystrophy, bladder disorders, and incontinence; and wherein the cognitive disorders and diseases are selected from the group consisting of Alzheimer's Disease, forms of memory loss, and age-dependent memory loss. 17. The method of claim 16, wherein the compound is administered to the subject to treat cardiac disorders and diseases selected from the group consisting of irregular heartbeat disorders and diseases; exercise-induced irregular heartbeat disorders and diseases; congestive heart failure; chronic obstructive pulmonary disease; and high blood pressure. 18. The method of claim 17, wherein the irregular heartbeat disorders and diseases and exercise-induced irregular heartbeat disorders and diseases are selected from the group consisting of atrial and ventricular arrhythmia; atrial and ventricular fibrillation; atrial and ventricular tachyarrhythmia; atrial and ventricular tachycardia; catecholaminergic polymorphic ventricular tachycardia (CPVT); and exercise-induced variants thereof. 19. The method of claim 16, wherein the compound is administered to the subject to treat skeletal muscular disorders and diseases selected from the group consisting of skeletal muscle fatigue, exercise-induced skeletal muscle fatigue, muscular dystrophy, bladder disorders, and incontinence. 20. The method of claim 16, wherein the compound is administered to the subject to treat cognitive disorders and diseases selected from the group consisting of Alzheimer's Disease, forms of memory loss, and age-dependent memory loss.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (133)
Reifschneider Walter (Walnut Creek CA) Bisabri-Ershadi Barat (Davis CA) Dripps James E. (Concord CA) Barron J. Brian (Benicia CA), ((N-heterocyclyl)carbonyl)phosphoramidothioate ester insecticides.
Reifschneider Walter (Walnut Creek CA) Bisabri-Ershadi Barat (Davis CA) Dripps James E. (Concord CA) Barron J. Brian (Benicia CA), ((N-heterocyclyl)carbonyl)phosphoramidothioate ester insecticides.
Husa Robert K. (Vernon Hills IL) Rafferty Michael F. (Buffalo Grove IL) Hagen Timothy J. (Glenview IL) Hallinan E. Ann (Evanston IL), 1-,2-,3-,4-,5-,6-,7-,8- and/or 9 substituted dibenzoxazepine compounds, pharmaceutical compositions and methods for trea.
Husa Robert K. (Vernon Hills IL) Hallinan E. Ann (Evanston IL) Lesne Michel (Kraainem BEX) Herin Marc (Montignies sur Sambre BEX), 2- and 3-alkoxy or hydroxy-8-substituted-dibenz[b,f]-[1,4]oxazepine-10(11H)-carboxylic acid, substituted hydrazides and.
Hansen ; Jr. Donald W. (Skokie IL) Peterson Karen B. (Vernon Hills IL), 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9- and/or 10-substituted dibenzoxazepine and dibenzthiazepine compounds, pharmaceutical comp.
Hagen Timothy J. (Glenview IL) Clare Michael (Skokie IL) Rafferty Michael F. (Buffalo Grove IL) Hallinan E. Ann (Evanston IL), 2-, 3-, 5-, 8-, 10- and/or 11-substituted dibenzoxazepine compounds, pharmaceutical compositions and methods for treatin.
Hansen ; Jr. Donald W. (Skokie IL) Peterson Karen B. (Vernon Hills IL), 2-,3-,4-,5-,6-,7-,8-,9- and/or 10-substituted dibenzoxazepine and dibenzthiazepine compounds, pharmaceutical composition.
Lawson John A. (Redwood City CA) Pandey Anjali (Menlo Park CA) Yasuda Dennis (Campbell CA) Tanabe Masato (Palo Alto CA), 2-piperidinecarboxylic acid derivatives useful as NMDA receptor antagonists.
Hallinan E. Ann (Evanston IL) Husa Robert K. (Vernon Hills IL) Peterson Karen B. (Vernon Hills IL), 8-substituted-dibenz[b,f][1,4]oxazepine-10(11)-carboxylic acid, substituted hydrazides, pharmaceutical compositions, and.
Koeller, Kevin J.; Tremont, Samuel J., Alkyl/aryl hydroxy or keto thiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake.
Ronald Keith Webber ; Richard C. Durley ; Alok K. Awasthi ; Arija A. Bergmanis ; Scott S. Ganser ; Timothy J. Hagen ; E. Ann Hallinan ; Donald W. Hansen, Jr. ; Brian S. Hickory ; Alan E. Moo, Amidino compound and salts thereof useful as nitric oxide synthase inhibitors.
Webber, Ronald Keith; Durley, Richard C.; Awasthi, Alok K.; Bergmanis, Arija A.; Fok, Kam F.; Ganser, Scott S.; Hagen, Timothy J.; Hallinan, E. Ann; Hansen, Jr., Donald W.; Hickory, Brian S.; Manning, Amidino compounds useful as nitric oxide synthase inhibitors.
Webber, Ronald Keith; Durley, Richard C.; Awasthi, Alok K.; Bergmanis, Arija A.; Fok, Kam F.; Ganser, Scott S.; Hagen, Timothy J.; Hallinan, E. Ann; Hansen, Jr., Donald W.; Hickory, Brian S.; Manning, Amidino compounds useful as nitric oxide synthase inhibitors.
Laborde, Edgardo; Robinson, Louise; Meng, Fanying; Peterson, Brian T.; Villar, Hugo O.; Anuskiewicz, Steven E.; Ma, Wenli; Matsumoto, Yukiharu; Baba, Kunihisa; Inagaki, Hideaki; Tanaka, Katsumasa; Is, Antagonist of MCP-1 function, and compositions and methods of use thereof.
Tomizuka, Kazuma; Yoshida, Hitoshi; Hanaoka, Kazunori; Oshimura, Mitsuo; Ishida, Isao, Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene.
Matsumoto Takashi (Stockholm SEX) Okada Takashi (Tokyo JPX) Mizusaki Shigenobu (Tokyo JPX), Desmosine derivatives having a disulfide bond and preparation of artificial antigen using the same.
Donald W. Hansen, Jr. ; Ronald Keith Webber ; Alok K. Awasthi ; Pamela T. Manning, Halogenated 2-amino-4, 5 heptenoic acid derivatives useful as nitric oxide synthase inhibitors.
Margaret L. Grapperhaus ; James A. Sikorski ; Alok K. Awasthi ; Lijuan J. Wang ; Barnett S. Pitzele ; Donald W. Hansen, Jr. ; Pamela T. Manning, Halogenated 2-amino-5,6 heptenoic acid derivatives useful as nitric oxide synthase inhibitors.
Donald W. Hansen, Jr. ; Jeffrey S. Snyder ; Alan E. Moormann ; Alok K. Awasthi ; Ronald Keith Webber ; Thaddeus S. Franczyk ; Mahima Trivedi, Homoiminopiperidinyl hexanoic acid inhibitors of inducible nitric oxide synthase.
Koezuka,Yasuhiko; Yamaguchi,Yasunori; Motoki,Kazuhiro, Method for activating human antigen-presenting cells, activated human antigen-presenting cells, and use thereof.
Tang, Y. Tom; Labat, Ivan; Drmanac, Radoje T.; Mize, Nancy; Nishikawa, Mitsuo; Chao, Cheng-Chi, Method of promoting stem cell proliferation or survival by contacting a cell with a stem cell factor-like polypeptide.
Chubinskaya, Susan; Hutchins, Jeff; Mollenhauer, Juergen; Tavares, Francis X.; Thomson, Stephen A.; Worley, Jennings F., Methods and compositions related to modulators of annexin and cartilage homeostasis.
Marks,Andrew Robert, Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2).
Andrew R. Marks ; Steven O. Marx, Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor.
Tandon,Narendra Nath; Sun,Bing; Nakamura,Takashi; Yamamoto,Naomasa, Platelet membrane glycoprotein VI (GPVI) DNA and protein sequences, and uses thereof.
Ishizaki Keiichirou (Kitsuregawa JPX) Onishi Noboru (Kitsuregawa JPX), Process for producing plantlets whereby the formation of a cell mass is induced.
McGee, Lawrence R.; Houze, Jonathan B.; Rubenstein, Steven M.; Hagiwara, Atsushi; Furukawa, Noboru; Shinkai, Hisashi, Quinolinyl and benzothiazolyl modulators.
Chandrakumar Nizal S. (Vernon Hills IL) Hansen ; Jr. Donald W. (Skokie IL) Peterson Karen B. (Vernon Hills IL) Pitzele Barnett S. (Skokie IL), Substituted dibenzoxazepine and dibenzthiazepine urea compounds, pharmaceutical compositions and methods of use.
Housley John R. (Nottingham GB2) Jeffery James E. (Nottingham GB2) Nichol Kenneth J. (Nottingham GB2) Sargent Bruce J. (Nottingham GB2), Therapeutic 1,4-thiazepines.
Askanazi Jeffrey (233 Myrtle St. Haworth NJ 07641) Trimbo Susan (737 Ridge Ave. Evanston IL 60202), Use of branched chain amino acids to effect diaphragm contractility and fatigue.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.